This "Harvard Blood Scholars" Career Development Award application is aimed as a renewal of the K12 Career Development Program in non-malignant hematology and transfusion medicine among a consortium of hematology training programs at Harvard Medical School-affiliated hospitals. The key rationale for this program is the need to reverse a long-term trend of graduates of hematology/oncology fellowship programs away from benign hematology practice and research. The first cycle of the program began in 2006. Six scholars, from three of the member hospital programs, matriculated in the first five years of NHLBI support, in diverse areas of hematology as defined for the program, to include myeloproliferative disorders and myelodysplastic syndrome, cell therapy (including gene therapy) and transfusion medicine, and traditional disciplines of non-malignant hematology including thrombosis and hemostasis, coagulation, anemias, marrow failure, disorders of neutrophils, iron-related diseases, and health-services research relating to these disorders. The program director, Dr. Ellis Neufeld, is a pediatric hematologist and geneticist involved in clinica trials of ITP, iron overload, and bleeding disorders, as well as lab-based genetic studies of inherited blood disorders. An advisory committee representing the institutions and broad variety of research interests serves as admissions committee and oversees the activities of the program. The prime candidate pool for K12 Blood Scholars includes pediatric and adult hematology, hematology/oncology and transfusion medicine fellows and instructors not only from the several training programs of our constituent hospitals, but also from junior physician-scientists of similar rank and interests from around the country. Most scholars will pursue two year career development programs. A third year of support may be available in some cases. Key components of the program include (a) formal training in methodology for patient oriented research, exemplified by the Harvard Medical Area's three Masters programs in Clinical Sciences, Clinical Effectiveness or Epidemiology, and Translational Research, and a mentored research project. A Blood Scholars Colloquium Series meets monthly, providing the entire Harvard Hematology community with cutting-edge research talks on patient- oriented studies in the disciplines of the grant. Each scholar develops with his/her mentors and the Advisory Committee an Individualized Curriculum Plan that takes into account the training level, background, and needs of the scholar for optimum career development. The key short-term metrics of the program are the demographics of the applicant and matriculating scholars, and the fraction of graduates who (a) apply for, and (b) receive advanced training grants in hematologic research particularly K23 or K08 grants. In the long run, the career choices and academic success of the graduates will be of paramount importance.

Public Health Relevance

Hundreds of unique diseases affect the blood;non-malignant hematology is the field of study of these disorders, excluding only the leukemias, or blood cancers. Although remarkable progress in hematology has fueled (and been fueled by) many of the key discoveries in modern medicine, the field is at risk from insufficient numbers of talented young physician scientists choosing to focus on blood disease. By providing expert training in research methods, and by convening an outstanding faculty of hematologists from across the several Harvard hospitals, this K12 Blood Scholars grant aims to launch the careers of the hematologist physician-scientists of the future.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12HL087164-07
Application #
8536350
Study Section
Special Emphasis Panel (ZHL1-CSR-J (F1))
Program Officer
Mondoro, Traci
Project Start
2006-09-28
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$394,826
Indirect Cost
$29,246
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Okam, Maureen M; Shaykevich, Shimon; Ebert, Benjamin L et al. (2014) National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care 52:612-8
Schoettler, Michelle; Elisofon, Scott A; Kim, Heung Bae et al. (2014) Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer :
Peña, Jeremy Ryan A; Saidman, Susan L; Girouard, Timothy C et al. (2014) Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion. Am J Hematol 89:E133-7
Grace, Rachael F (2013) Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia. Semin Hematol 50 Suppl 1:S31-8
Sobota, Amy; Graham, Dionne A; Heeney, Matthew M et al. (2010) Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol 85:24-8
Heeney, Matthew M; Ware, Russell E (2010) Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 24:199-214
George, Mathew; Heeney, Matthew M; Woolf, Alan D (2010) Encephalopathy from lead poisoning masquerading as a flu-like syndrome in an autistic child. Pediatr Emerg Care 26:370-3
Anderson, Damon S; Heeney, Matthew M; Roth, Udo et al. (2010) High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine. Anal Chem 82:1551-5
Morrissey, Lisa K; Shea, Joan O'Brien; Kalish, Leslie A et al. (2009) Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer 52:369-72
Chirnomas, Deborah; Smith, Amber Lynn; Braunstein, Jennifer et al. (2009) Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114:4009-13

Showing the most recent 10 out of 11 publications